Global Vebreltinib Enteric Capsules Market Growth 2025-2031

Product Code: 1560218

Industry: Pharma & Healthcare

Published: Jul 11,2025

Pages: 79

Delivery Time: 2-3 business days

Global Vebreltinib Enteric Capsules Market Growth 2025-2031

Product Code: 1560218

Industry: Pharma & Healthcare

Published: Jul 11,2025

Pages: 79

Delivery Time: 2-3 business days

Select A Format

Single User License

USD3660

Multi Users License

USD5490

Corporate Users License

USD7320

Buy Now

Add To Cart

Or More Options：

PDF Download

Sample Request

Custom Request

Provide market analysis and obtain sources of data reports

Description

The global Vebreltinib Enteric Capsules market size is predicted to grow from US$ 3.7 million in 2025 to US$ 23.9 million in 2031; it is expected to grow at a CAGR of 36.7% from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Vebreltinib enteric capsules are designed to provide targeted therapy for patients with MET exon 14 skipping mutations, a key oncogenic driver in non-small cell lung cancer (NSCLC) and other malignancies. As a selective MET receptor tyrosine kinase inhibitor, Vebreltinib effectively blocks MET signaling pathways, inhibiting tumor growth, proliferation, and metastasis.

In November 2023, Vebreltinib received conditional approval for the treatment of metastatic patients with MET Exon14 Skipping non-small cell lung cancer (NSCLC) from the NMPA. In China, the development rights for Vebreltinib Enteric Capsules are held by Purunao Biotech. In December 2021, Avistone announced the acquisition of Purunao Biotech, integrating Vebreltinib into its research and development pipeline. Outside mainland China, Hong Kong, and Macau, the development rights for Vebreltinib are owned by Apollomics. It is still in the clinical trial stage and has not yet been commercialized in the United States. If all goes well, it is expected to be approved by the FDA in the next few years.

At present, Vebreltinib enteric capsules have established a clear foothold in the Chinese pharmaceutical market by addressing key unmet needs in MET exon 14 skipping NSCLC and PTPRZ1-MET fusion-positive glioblastomas. As one of the first MET-targeted therapies approved in China, it has shown superior efficacy compared to existing options and has gained strong acceptance among clinicians. Its inclusion in the National Reimbursement Drug List (NRDL) significantly boosts patient access and accelerates market penetration, reinforcing its role as a leading precision oncology therapy.

Looking forward, Vebreltinib is rapidly advancing toward broader indications such as MET-amplified NSCLC. Its priority review status and active clinical pipeline position it as a central agent in China's evolving precision oncology landscape. Coupled with favorable healthcare policies that support innovative drug access and expedited regulatory review processes, Vebreltinib stands to benefit from an environment that actively promotes novel targeted therapies. This alignment between scientific innovation and policy support creates a strong foundation for long-term commercial success.

Nonetheless, the market presents challenges. The relatively small patient population with MET-driven mutations limits the addressable market. Furthermore, the emergence of global competitors—such as Capmatinib and Tepotinib—poses a threat should they enter the Chinese market. Internationally, Vebreltinib has yet to achieve commercialization, with clinical trials still underway and regulatory approvals pending. Therefore, its global expansion hinges on successful regulatory milestones, particularly FDA approval. Continued clinical validation, strategic regulatory navigation, and the establishment of global commercialization partnerships will be critical for sustaining future growth beyond China.

LP Information, Inc. (LPI) ' newest research report, the “Vebreltinib Enteric Capsules Industry Forecast” looks at past sales and reviews total world Vebreltinib Enteric Capsules sales in 2024, providing a comprehensive analysis by region and market sector of projected Vebreltinib Enteric Capsules sales for 2025 through 2031. With Vebreltinib Enteric Capsules sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Vebreltinib Enteric Capsules industry.

This Insight Report provides a comprehensive analysis of the global Vebreltinib Enteric Capsules landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Vebreltinib Enteric Capsules portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Vebreltinib Enteric Capsules market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Vebreltinib Enteric Capsules and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vebreltinib Enteric Capsules.

This report presents a comprehensive overview, market shares, and growth opportunities of Vebreltinib Enteric Capsules market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
25mg
100mg

Segmentation by Application:
Non-small Cell Lung Cancer
Glioma

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Avistone
Apollomics

Key Questions Addressed in this Report
What is the 10-year outlook for the global Vebreltinib Enteric Capsules market?
What factors are driving Vebreltinib Enteric Capsules market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Vebreltinib Enteric Capsules market opportunities vary by end market size?
How does Vebreltinib Enteric Capsules break out by Type, by Application?

Table Of Contents

1 Scope of the Report
    1.1 Market Introduction
    1.2 Years Considered
    1.3 Research Objectives
    1.4 Market Research Methodology
    1.5 Research Process and Data Source
    1.6 Economic Indicators
    1.7 Currency Considered
    1.8 Market Estimation Caveats

2 Executive Summary
    2.1 World Market Overview
        2.1.1 Global Vebreltinib Enteric Capsules Annual Sales 2020-2031
        2.1.2 World Current & Future Analysis for Vebreltinib Enteric Capsules by Geographic Region, 2020, 2024 & 2031
        2.1.3 World Current & Future Analysis for Vebreltinib Enteric Capsules by Country/Region, 2020, 2024 & 2031
    2.2 Vebreltinib Enteric Capsules Segment by Type
        2.2.1 25mg
        2.2.2 100mg
    2.3 Vebreltinib Enteric Capsules Sales by Type
        2.3.1 Global Vebreltinib Enteric Capsules Sales Market Share by Type (2020-2025)
        2.3.2 Global Vebreltinib Enteric Capsules Revenue and Market Share by Type (2020-2025)
        2.3.3 Global Vebreltinib Enteric Capsules Sale Price by Type (2020-2025)
    2.4 Vebreltinib Enteric Capsules Segment by Application
        2.4.1 Non-small Cell Lung Cancer
        2.4.2 Glioma
    2.5 Vebreltinib Enteric Capsules Sales by Application
        2.5.1 Global Vebreltinib Enteric Capsules Sale Market Share by Application (2020-2025)
        2.5.2 Global Vebreltinib Enteric Capsules Revenue and Market Share by Application (2020-2025)
        2.5.3 Global Vebreltinib Enteric Capsules Sale Price by Application (2020-2025)

3 Global by Company
    3.1 Global Vebreltinib Enteric Capsules Breakdown Data by Company
        3.1.1 Global Vebreltinib Enteric Capsules Annual Sales by Company (2020-2025)
        3.1.2 Global Vebreltinib Enteric Capsules Sales Market Share by Company (2020-2025)
    3.2 Global Vebreltinib Enteric Capsules Annual Revenue by Company (2020-2025)
        3.2.1 Global Vebreltinib Enteric Capsules Revenue by Company (2020-2025)
        3.2.2 Global Vebreltinib Enteric Capsules Revenue Market Share by Company (2020-2025)
    3.3 Global Vebreltinib Enteric Capsules Sale Price by Company
    3.4 Key Manufacturers Vebreltinib Enteric Capsules Producing Area Distribution, Sales Area, Product Type
        3.4.1 Key Manufacturers Vebreltinib Enteric Capsules Product Location Distribution
        3.4.2 Players Vebreltinib Enteric Capsules Products Offered
    3.5 Market Concentration Rate Analysis
        3.5.1 Competition Landscape Analysis
        3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
    3.6 New Products and Potential Entrants
    3.7 Market M&A Activity & Strategy

4 World Historic Review for Vebreltinib Enteric Capsules by Geographic Region
    4.1 World Historic Vebreltinib Enteric Capsules Market Size by Geographic Region (2020-2025)
        4.1.1 Global Vebreltinib Enteric Capsules Annual Sales by Geographic Region (2020-2025)
        4.1.2 Global Vebreltinib Enteric Capsules Annual Revenue by Geographic Region (2020-2025)
    4.2 World Historic Vebreltinib Enteric Capsules Market Size by Country/Region (2020-2025)
        4.2.1 Global Vebreltinib Enteric Capsules Annual Sales by Country/Region (2020-2025)
        4.2.2 Global Vebreltinib Enteric Capsules Annual Revenue by Country/Region (2020-2025)
    4.3 Americas Vebreltinib Enteric Capsules Sales Growth
    4.4 APAC Vebreltinib Enteric Capsules Sales Growth
    4.5 Europe Vebreltinib Enteric Capsules Sales Growth
    4.6 Middle East & Africa Vebreltinib Enteric Capsules Sales Growth

5 Americas
    5.1 Americas Vebreltinib Enteric Capsules Sales by Country
        5.1.1 Americas Vebreltinib Enteric Capsules Sales by Country (2020-2025)
        5.1.2 Americas Vebreltinib Enteric Capsules Revenue by Country (2020-2025)
    5.2 Americas Vebreltinib Enteric Capsules Sales by Type (2020-2025)
    5.3 Americas Vebreltinib Enteric Capsules Sales by Application (2020-2025)
    5.4 United States
    5.5 Canada
    5.6 Mexico
    5.7 Brazil

6 APAC
    6.1 APAC Vebreltinib Enteric Capsules Sales by Region
        6.1.1 APAC Vebreltinib Enteric Capsules Sales by Region (2020-2025)
        6.1.2 APAC Vebreltinib Enteric Capsules Revenue by Region (2020-2025)
    6.2 APAC Vebreltinib Enteric Capsules Sales by Type (2020-2025)
    6.3 APAC Vebreltinib Enteric Capsules Sales by Application (2020-2025)
    6.4 China
    6.5 Japan
    6.6 South Korea
    6.7 Southeast Asia
    6.8 India
    6.9 Australia
    6.10 China Taiwan

7 Europe
    7.1 Europe Vebreltinib Enteric Capsules by Country
        7.1.1 Europe Vebreltinib Enteric Capsules Sales by Country (2020-2025)
        7.1.2 Europe Vebreltinib Enteric Capsules Revenue by Country (2020-2025)
    7.2 Europe Vebreltinib Enteric Capsules Sales by Type (2020-2025)
    7.3 Europe Vebreltinib Enteric Capsules Sales by Application (2020-2025)
    7.4 Germany
    7.5 France
    7.6 UK
    7.7 Italy
    7.8 Russia

8 Middle East & Africa
    8.1 Middle East & Africa Vebreltinib Enteric Capsules by Country
        8.1.1 Middle East & Africa Vebreltinib Enteric Capsules Sales by Country (2020-2025)
        8.1.2 Middle East & Africa Vebreltinib Enteric Capsules Revenue by Country (2020-2025)
    8.2 Middle East & Africa Vebreltinib Enteric Capsules Sales by Type (2020-2025)
    8.3 Middle East & Africa Vebreltinib Enteric Capsules Sales by Application (2020-2025)
    8.4 Egypt
    8.5 South Africa
    8.6 Israel
    8.7 Turkey
    8.8 GCC Countries

9 Market Drivers, Challenges and Trends
    9.1 Market Drivers & Growth Opportunities
    9.2 Market Challenges & Risks
    9.3 Industry Trends

10 Manufacturing Cost Structure Analysis
    10.1 Raw Material and Suppliers
    10.2 Manufacturing Cost Structure Analysis of Vebreltinib Enteric Capsules
    10.3 Manufacturing Process Analysis of Vebreltinib Enteric Capsules
    10.4 Industry Chain Structure of Vebreltinib Enteric Capsules

11 Marketing, Distributors and Customer
    11.1 Sales Channel
        11.1.1 Direct Channels
        11.1.2 Indirect Channels
    11.2 Vebreltinib Enteric Capsules Distributors
    11.3 Vebreltinib Enteric Capsules Customer

12 World Forecast Review for Vebreltinib Enteric Capsules by Geographic Region
    12.1 Global Vebreltinib Enteric Capsules Market Size Forecast by Region
        12.1.1 Global Vebreltinib Enteric Capsules Forecast by Region (2026-2031)
        12.1.2 Global Vebreltinib Enteric Capsules Annual Revenue Forecast by Region (2026-2031)
    12.2 Americas Forecast by Country (2026-2031)
    12.3 APAC Forecast by Region (2026-2031)
    12.4 Europe Forecast by Country (2026-2031)
    12.5 Middle East & Africa Forecast by Country (2026-2031)
    12.6 Global Vebreltinib Enteric Capsules Forecast by Type (2026-2031)
    12.7 Global Vebreltinib Enteric Capsules Forecast by Application (2026-2031)

13 Key Players Analysis
    13.1 Avistone
        13.1.1 Avistone Company Information
        13.1.2 Avistone Vebreltinib Enteric Capsules Product Portfolios and Specifications
        13.1.3 Avistone Vebreltinib Enteric Capsules Sales, Revenue, Price and Gross Margin (2020-2025)
        13.1.4 Avistone Main Business Overview
        13.1.5 Avistone Latest Developments
    13.2 Apollomics
        13.2.1 Apollomics Company Information
        13.2.2 Apollomics Vebreltinib Enteric Capsules Product Portfolios and Specifications
        13.2.3 Apollomics Vebreltinib Enteric Capsules Sales, Revenue, Price and Gross Margin (2020-2025)
        13.2.4 Apollomics Main Business Overview
        13.2.5 Apollomics Latest Developments

14 Research Findings and Conclusion

List Of Tables

List of Tables
 Table 1. Vebreltinib Enteric Capsules Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
 Table 2. Vebreltinib Enteric Capsules Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
 Table 3. Major Players of 25mg
 Table 4. Major Players of 100mg
 Table 5. Global Vebreltinib Enteric Capsules Sales by Type (2020-2025) & (K Units)
 Table 6. Global Vebreltinib Enteric Capsules Sales Market Share by Type (2020-2025)
 Table 7. Global Vebreltinib Enteric Capsules Revenue by Type (2020-2025) & ($ million)
 Table 8. Global Vebreltinib Enteric Capsules Revenue Market Share by Type (2020-2025)
 Table 9. Global Vebreltinib Enteric Capsules Sale Price by Type (2020-2025) & (US$/Unit)
 Table 10. Global Vebreltinib Enteric Capsules Sale by Application (2020-2025) & (K Units)
 Table 11. Global Vebreltinib Enteric Capsules Sale Market Share by Application (2020-2025)
 Table 12. Global Vebreltinib Enteric Capsules Revenue by Application (2020-2025) & ($ million)
 Table 13. Global Vebreltinib Enteric Capsules Revenue Market Share by Application (2020-2025)
 Table 14. Global Vebreltinib Enteric Capsules Sale Price by Application (2020-2025) & (US$/Unit)
 Table 15. Global Vebreltinib Enteric Capsules Sales by Company (2020-2025) & (K Units)
 Table 16. Global Vebreltinib Enteric Capsules Sales Market Share by Company (2020-2025)
 Table 17. Global Vebreltinib Enteric Capsules Revenue by Company (2020-2025) & ($ millions)
 Table 18. Global Vebreltinib Enteric Capsules Revenue Market Share by Company (2020-2025)
 Table 19. Global Vebreltinib Enteric Capsules Sale Price by Company (2020-2025) & (US$/Unit)
 Table 20. Key Manufacturers Vebreltinib Enteric Capsules Producing Area Distribution and Sales Area
 Table 21. Players Vebreltinib Enteric Capsules Products Offered
 Table 22. Vebreltinib Enteric Capsules Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
 Table 23. New Products and Potential Entrants
 Table 24. Market M&A Activity & Strategy
 Table 25. Global Vebreltinib Enteric Capsules Sales by Geographic Region (2020-2025) & (K Units)
 Table 26. Global Vebreltinib Enteric Capsules Sales Market Share Geographic Region (2020-2025)
 Table 27. Global Vebreltinib Enteric Capsules Revenue by Geographic Region (2020-2025) & ($ millions)
 Table 28. Global Vebreltinib Enteric Capsules Revenue Market Share by Geographic Region (2020-2025)
 Table 29. Global Vebreltinib Enteric Capsules Sales by Country/Region (2020-2025) & (K Units)
 Table 30. Global Vebreltinib Enteric Capsules Sales Market Share by Country/Region (2020-2025)
 Table 31. Global Vebreltinib Enteric Capsules Revenue by Country/Region (2020-2025) & ($ millions)
 Table 32. Global Vebreltinib Enteric Capsules Revenue Market Share by Country/Region (2020-2025)
 Table 33. Americas Vebreltinib Enteric Capsules Sales by Country (2020-2025) & (K Units)
 Table 34. Americas Vebreltinib Enteric Capsules Sales Market Share by Country (2020-2025)
 Table 35. Americas Vebreltinib Enteric Capsules Revenue by Country (2020-2025) & ($ millions)
 Table 36. Americas Vebreltinib Enteric Capsules Sales by Type (2020-2025) & (K Units)
 Table 37. Americas Vebreltinib Enteric Capsules Sales by Application (2020-2025) & (K Units)
 Table 38. APAC Vebreltinib Enteric Capsules Sales by Region (2020-2025) & (K Units)
 Table 39. APAC Vebreltinib Enteric Capsules Sales Market Share by Region (2020-2025)
 Table 40. APAC Vebreltinib Enteric Capsules Revenue by Region (2020-2025) & ($ millions)
 Table 41. APAC Vebreltinib Enteric Capsules Sales by Type (2020-2025) & (K Units)
 Table 42. APAC Vebreltinib Enteric Capsules Sales by Application (2020-2025) & (K Units)
 Table 43. Europe Vebreltinib Enteric Capsules Sales by Country (2020-2025) & (K Units)
 Table 44. Europe Vebreltinib Enteric Capsules Revenue by Country (2020-2025) & ($ millions)
 Table 45. Europe Vebreltinib Enteric Capsules Sales by Type (2020-2025) & (K Units)
 Table 46. Europe Vebreltinib Enteric Capsules Sales by Application (2020-2025) & (K Units)
 Table 47. Middle East & Africa Vebreltinib Enteric Capsules Sales by Country (2020-2025) & (K Units)
 Table 48. Middle East & Africa Vebreltinib Enteric Capsules Revenue Market Share by Country (2020-2025)
 Table 49. Middle East & Africa Vebreltinib Enteric Capsules Sales by Type (2020-2025) & (K Units)
 Table 50. Middle East & Africa Vebreltinib Enteric Capsules Sales by Application (2020-2025) & (K Units)
 Table 51. Key Market Drivers & Growth Opportunities of Vebreltinib Enteric Capsules
 Table 52. Key Market Challenges & Risks of Vebreltinib Enteric Capsules
 Table 53. Key Industry Trends of Vebreltinib Enteric Capsules
 Table 54. Vebreltinib Enteric Capsules Raw Material
 Table 55. Key Suppliers of Raw Materials
 Table 56. Vebreltinib Enteric Capsules Distributors List
 Table 57. Vebreltinib Enteric Capsules Customer List
 Table 58. Global Vebreltinib Enteric Capsules Sales Forecast by Region (2026-2031) & (K Units)
 Table 59. Global Vebreltinib Enteric Capsules Revenue Forecast by Region (2026-2031) & ($ millions)
 Table 60. Americas Vebreltinib Enteric Capsules Sales Forecast by Country (2026-2031) & (K Units)
 Table 61. Americas Vebreltinib Enteric Capsules Annual Revenue Forecast by Country (2026-2031) & ($ millions)
 Table 62. APAC Vebreltinib Enteric Capsules Sales Forecast by Region (2026-2031) & (K Units)
 Table 63. APAC Vebreltinib Enteric Capsules Annual Revenue Forecast by Region (2026-2031) & ($ millions)
 Table 64. Europe Vebreltinib Enteric Capsules Sales Forecast by Country (2026-2031) & (K Units)
 Table 65. Europe Vebreltinib Enteric Capsules Revenue Forecast by Country (2026-2031) & ($ millions)
 Table 66. Middle East & Africa Vebreltinib Enteric Capsules Sales Forecast by Country (2026-2031) & (K Units)
 Table 67. Middle East & Africa Vebreltinib Enteric Capsules Revenue Forecast by Country (2026-2031) & ($ millions)
 Table 68. Global Vebreltinib Enteric Capsules Sales Forecast by Type (2026-2031) & (K Units)
 Table 69. Global Vebreltinib Enteric Capsules Revenue Forecast by Type (2026-2031) & ($ millions)
 Table 70. Global Vebreltinib Enteric Capsules Sales Forecast by Application (2026-2031) & (K Units)
 Table 71. Global Vebreltinib Enteric Capsules Revenue Forecast by Application (2026-2031) & ($ millions)
 Table 72. Avistone Basic Information, Vebreltinib Enteric Capsules Manufacturing Base, Sales Area and Its Competitors
 Table 73. Avistone Vebreltinib Enteric Capsules Product Portfolios and Specifications
 Table 74. Avistone Vebreltinib Enteric Capsules Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 75. Avistone Main Business
 Table 76. Avistone Latest Developments
 Table 77. Apollomics Basic Information, Vebreltinib Enteric Capsules Manufacturing Base, Sales Area and Its Competitors
 Table 78. Apollomics Vebreltinib Enteric Capsules Product Portfolios and Specifications
 Table 79. Apollomics Vebreltinib Enteric Capsules Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 80. Apollomics Main Business
 Table 81. Apollomics Latest Developments


List of Figures
 Figure 1. Picture of Vebreltinib Enteric Capsules
 Figure 2. Vebreltinib Enteric Capsules Report Years Considered
 Figure 3. Research Objectives
 Figure 4. Research Methodology
 Figure 5. Research Process and Data Source
 Figure 6. Global Vebreltinib Enteric Capsules Sales Growth Rate 2020-2031 (K Units)
 Figure 7. Global Vebreltinib Enteric Capsules Revenue Growth Rate 2020-2031 ($ millions)
 Figure 8. Vebreltinib Enteric Capsules Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
 Figure 9. Vebreltinib Enteric Capsules Sales Market Share by Country/Region (2024)
 Figure 10. Vebreltinib Enteric Capsules Sales Market Share by Country/Region (2020, 2024 & 2031)
 Figure 11. Product Picture of 25mg
 Figure 12. Product Picture of 100mg
 Figure 13. Global Vebreltinib Enteric Capsules Sales Market Share by Type in 2025
 Figure 14. Global Vebreltinib Enteric Capsules Revenue Market Share by Type (2020-2025)
 Figure 15. Vebreltinib Enteric Capsules Consumed in Non-small Cell Lung Cancer
 Figure 16. Global Vebreltinib Enteric Capsules Market: Non-small Cell Lung Cancer (2020-2025) & (K Units)
 Figure 17. Vebreltinib Enteric Capsules Consumed in Glioma
 Figure 18. Global Vebreltinib Enteric Capsules Market: Glioma (2020-2025) & (K Units)
 Figure 19. Global Vebreltinib Enteric Capsules Sale Market Share by Application (2024)
 Figure 20. Global Vebreltinib Enteric Capsules Revenue Market Share by Application in 2025
 Figure 21. Vebreltinib Enteric Capsules Sales by Company in 2025 (K Units)
 Figure 22. Global Vebreltinib Enteric Capsules Sales Market Share by Company in 2025
 Figure 23. Vebreltinib Enteric Capsules Revenue by Company in 2025 ($ millions)
 Figure 24. Global Vebreltinib Enteric Capsules Revenue Market Share by Company in 2025
 Figure 25. Global Vebreltinib Enteric Capsules Sales Market Share by Geographic Region (2020-2025)
 Figure 26. Global Vebreltinib Enteric Capsules Revenue Market Share by Geographic Region in 2025
 Figure 27. Americas Vebreltinib Enteric Capsules Sales 2020-2025 (K Units)
 Figure 28. Americas Vebreltinib Enteric Capsules Revenue 2020-2025 ($ millions)
 Figure 29. APAC Vebreltinib Enteric Capsules Sales 2020-2025 (K Units)
 Figure 30. APAC Vebreltinib Enteric Capsules Revenue 2020-2025 ($ millions)
 Figure 31. Europe Vebreltinib Enteric Capsules Sales 2020-2025 (K Units)
 Figure 32. Europe Vebreltinib Enteric Capsules Revenue 2020-2025 ($ millions)
 Figure 33. Middle East & Africa Vebreltinib Enteric Capsules Sales 2020-2025 (K Units)
 Figure 34. Middle East & Africa Vebreltinib Enteric Capsules Revenue 2020-2025 ($ millions)
 Figure 35. Americas Vebreltinib Enteric Capsules Sales Market Share by Country in 2025
 Figure 36. Americas Vebreltinib Enteric Capsules Revenue Market Share by Country (2020-2025)
 Figure 37. Americas Vebreltinib Enteric Capsules Sales Market Share by Type (2020-2025)
 Figure 38. Americas Vebreltinib Enteric Capsules Sales Market Share by Application (2020-2025)
 Figure 39. United States Vebreltinib Enteric Capsules Revenue Growth 2020-2025 ($ millions)
 Figure 40. Canada Vebreltinib Enteric Capsules Revenue Growth 2020-2025 ($ millions)
 Figure 41. Mexico Vebreltinib Enteric Capsules Revenue Growth 2020-2025 ($ millions)
 Figure 42. Brazil Vebreltinib Enteric Capsules Revenue Growth 2020-2025 ($ millions)
 Figure 43. APAC Vebreltinib Enteric Capsules Sales Market Share by Region in 2025
 Figure 44. APAC Vebreltinib Enteric Capsules Revenue Market Share by Region (2020-2025)
 Figure 45. APAC Vebreltinib Enteric Capsules Sales Market Share by Type (2020-2025)
 Figure 46. APAC Vebreltinib Enteric Capsules Sales Market Share by Application (2020-2025)
 Figure 47. China Vebreltinib Enteric Capsules Revenue Growth 2020-2025 ($ millions)
 Figure 48. Japan Vebreltinib Enteric Capsules Revenue Growth 2020-2025 ($ millions)
 Figure 49. South Korea Vebreltinib Enteric Capsules Revenue Growth 2020-2025 ($ millions)
 Figure 50. Southeast Asia Vebreltinib Enteric Capsules Revenue Growth 2020-2025 ($ millions)
 Figure 51. India Vebreltinib Enteric Capsules Revenue Growth 2020-2025 ($ millions)
 Figure 52. Australia Vebreltinib Enteric Capsules Revenue Growth 2020-2025 ($ millions)
 Figure 53. China Taiwan Vebreltinib Enteric Capsules Revenue Growth 2020-2025 ($ millions)
 Figure 54. Europe Vebreltinib Enteric Capsules Sales Market Share by Country in 2025
 Figure 55. Europe Vebreltinib Enteric Capsules Revenue Market Share by Country (2020-2025)
 Figure 56. Europe Vebreltinib Enteric Capsules Sales Market Share by Type (2020-2025)
 Figure 57. Europe Vebreltinib Enteric Capsules Sales Market Share by Application (2020-2025)
 Figure 58. Germany Vebreltinib Enteric Capsules Revenue Growth 2020-2025 ($ millions)
 Figure 59. France Vebreltinib Enteric Capsules Revenue Growth 2020-2025 ($ millions)
 Figure 60. UK Vebreltinib Enteric Capsules Revenue Growth 2020-2025 ($ millions)
 Figure 61. Italy Vebreltinib Enteric Capsules Revenue Growth 2020-2025 ($ millions)
 Figure 62. Russia Vebreltinib Enteric Capsules Revenue Growth 2020-2025 ($ millions)
 Figure 63. Middle East & Africa Vebreltinib Enteric Capsules Sales Market Share by Country (2020-2025)
 Figure 64. Middle East & Africa Vebreltinib Enteric Capsules Sales Market Share by Type (2020-2025)
 Figure 65. Middle East & Africa Vebreltinib Enteric Capsules Sales Market Share by Application (2020-2025)
 Figure 66. Egypt Vebreltinib Enteric Capsules Revenue Growth 2020-2025 ($ millions)
 Figure 67. South Africa Vebreltinib Enteric Capsules Revenue Growth 2020-2025 ($ millions)
 Figure 68. Israel Vebreltinib Enteric Capsules Revenue Growth 2020-2025 ($ millions)
 Figure 69. Turkey Vebreltinib Enteric Capsules Revenue Growth 2020-2025 ($ millions)
 Figure 70. GCC Countries Vebreltinib Enteric Capsules Revenue Growth 2020-2025 ($ millions)
 Figure 71. Manufacturing Cost Structure Analysis of Vebreltinib Enteric Capsules in 2025
 Figure 72. Manufacturing Process Analysis of Vebreltinib Enteric Capsules
 Figure 73. Industry Chain Structure of Vebreltinib Enteric Capsules
 Figure 74. Channels of Distribution
 Figure 75. Global Vebreltinib Enteric Capsules Sales Market Forecast by Region (2026-2031)
 Figure 76. Global Vebreltinib Enteric Capsules Revenue Market Share Forecast by Region (2026-2031)
 Figure 77. Global Vebreltinib Enteric Capsules Sales Market Share Forecast by Type (2026-2031)
 Figure 78. Global Vebreltinib Enteric Capsules Revenue Market Share Forecast by Type (2026-2031)
 Figure 79. Global Vebreltinib Enteric Capsules Sales Market Share Forecast by Application (2026-2031)
 Figure 80. Global Vebreltinib Enteric Capsules Revenue Market Share Forecast by Application (2026-2031)

Companies Mentioned

Avistone

Apollomics

Methodology

LP Information presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

Data Sourse

Primary Source

Secondary Source

Players/Suppliers

Journals and Periodicals

Industry Experts

Government Bodies

Distributors/Traders

Annual Reports

Opinion Leaders

Presentations

Front-line Staff